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Summary We have assessed the effects of clodronate (dichloromethylene diphosphonate; C12MDP 0.8-3.2g
daily by mouth for up to 3 months) in 17 episodes of hypercalcaemia and osteolysis due to carcinoma.
Clodronate reduced serum calcium in 14 episodes and bone resorption in all patients. These remained
suppressed for the duration of treatment, but recurred promptly when treatment was stopped. Clodronate
may be a useful measure for controlling hypercalcaemia and osteolysis in patients with carcinoma.
Secondary carcinoma affecting the skeleton is the
most common cause of hypercalcaemia in
hospitalized patients (Fisken et al., 1980), and
usually indicates a poor prognosis. Prompt effective
treatment may decrease morbidity allowing
hospitalised patients to return home, and in some
instances, enable them to tolerate additional
treatment more readily. Our understanding of the
pathogenesis of hypercalcaemia in carcinoma is
incomplete. It is usually but not invariably
associated with widespread skeletal metastases. The
increased bone resorption may be accompanied by
increased activity of osteoclasts but a direct effect
of the tumour cells themselves on bone is also a
possible mechanism (Stewart et al., 1982). Rarely,
hypercalcaemia is associated with increased bone
resorption, but without obvious skeletal deposits
(Mundy et al., 1984) and is though to be mediated
by humoral mechanisms not yet well characterised
(Stewart et al., 1983; Strewler et al., 1983).
Adequate extracellular volume repletion is an
important aspect of the treatment of hyper-
calcaemia which decreases renal tubular re-
absorption of calcium and increases glomerular
filtration and thus the filtered load of calcium
(Hosking et al., 1981). Agents which inhibit
specifically osteoclast activity have also been used,
including calcitonin, corticosteroids and mithra-
mycin. However, the response to calcitonin is
commonly variable and incomplete (Wilkinson,
1984) steroids are not always effective (Percival et
al., 1984; Mundy et al., 1983) and mithramycin has
toxic effects on bone marrow and liver (Stewart,
1983), particulary if used with other cytotoxic
agents. More recently, the use of several diphos-
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phonates, has given encouraging results in the
treatment of hypercalcaemia (Jung et al., 1981;
Chapuy et al., 1980; van Breukelen et al., 1979).
We have used clodronate (dichoromethylene
diphosphonate) in patients with hypercalcaemia of
various causes. Our results in myeloma have been
reported elsewhere (Paterson et al., 1983), and we
report here our findings in patients with hyper-
calcaemia due to solid tumours.
Patients and methods
Seventeen episodes of hypercalcaemia were studied
in 15 patients (9 women and 6 men) with
disseminated carcinoma before and after treatment
with clodronate (Table I). Two patients (nos. 3 and
7) received a second course of clodronate which
was separated by a treatment free interval of 5-6
weeks.
Patients were admitted to the study if their values
for serum calcium were above normal (2.1-
2.6mmoll-1) and either stable or rising in a 48h
control period despite adequate hydration. Six of
the patients had received prednisolone (10-40mg
daily), but had failed to show any hypocalcaemic
response despite treatment for 12 to 28 days. Where
hypocalcaemic agents (including i.v. fluids or
corticosteroids) were being administered in the
period before treatment, these were continued in
the same dose during the early period of treatment.
All patients had scintigraphic or radiographic
evidence of widespread skeletal metastases and one
third had biochemical evidence for hepatic
dysfunction.
Informed consent was obtained from all patients
or from a relative where the patient was unfit to
give consent. The study had the prior approval of
the local Ethical Committee.
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Table I Details of patients studied
Duration of
Serum calcium Dose of treatment Concurrent
Patient Sex Age Primary carcinoma (mmol1I) clodronate (gd-1) (weeks) therapy
I F 57 Parathyroid 3.79 3.2 10
2 M 55 Bronchus 2.91 3.2 0.5 prednisolone
3 M 72 Larynx 3.05 1.6 2 prednisolone
3.59 1.6 2
4 M 62 Bronchus 3.69 3.2 12
5 M 50 Adenocarcinoma 2.94 1.6 6
(site unknown)
6 M 48 Hypernephroma 3.27 3.2 10 medroxyprogesterone
7 M 72 Prostate 3.65 3.2 3
3.76 3.2 6
8 F 32 Breast 3.13 3.2 3 prednisolone
9 F 43 Breast 2.91 1.6 5 prednisolone
10 F 43 Breast 2.99 3.2 5
11 F 48 Breast 2.83 3.2 8 prednisolone
12 F 52 Breast 3.10 1.6 3
13 F 57 Breast 3.16 1.6 8
14 F 49 Breast 3.28 1.6 5 prednisolone
15 F 68 Breast 2.80 1.6 4
All patients were fully hydrated as judged by
clinical criteria before the start of treatment with
clodronate. Clodronate was given by mouth in a
single daily dose of 0.8-3.2g 2h before breakfast.
This range of dose was chosen because earlier
studies had shown this to be effective in Paget's
disease and hypercalcaemia due to myeloma
(Douglas et al., 1980; Paterson et al., 1983).
Patients were treated for periods ranging from 3
days to 3 months (Table I).
After an overnight fast, urine was collected
during a 2h period before breakfast. A venous
blood sample was obtained during this period and
the serum separated. Calcium, phosphate, creatinine
and albumin were measured in serum by a
Technicon SMAC Autoanalyser. Serum calcium
was adjusted for variations in serum albumin by
the addition or subtraction of 0.02mmol 1- for
each g 1 - that albumin was below or above 42g/1.
Urinary calcium and hydroxyproline were expressed
as ratios of urinary creatinine, which in the fasting
state provided indices of net calcium release from
bone and of bone resorption (Nordin, 1976; Cundy
et al., 1983).
The significance of changes in mean values was
computed using Student's t-test for paired or non-
paired observations as appropriate. Results are
shown as means (±s.e.).
Results
The administration of clodronate resulted in a
progressive fall in serum calcium in 14 of the 17
episodes studied. The maximum effect on serum
calcium was seen one week after starting treatment.
Mean serum calcium fell from 3.23+0.08mmoll-'
to 2.85+0.09mmoll-1 at 1 week (Figure 1), and
normal values for serum calcium were observed in 9
patients. In 14 studies (on 13 patients) treatment
was continued for 3 to 10 weeks. In all but 4
patients a hypocalcaemic response was sustained
for the duration of treatment though mean values
rose slightly (Figure 1). Mean serum creatinine did
not change throughout treatment (130+20jumolI1
before treatment and 137+ 19pmol 1 1 at 1 week)
and no changes in haematocrit or serum albumin
were observed suggesting that changes in serum
calcium could not be ascribed to changes in
rehydration or to improved renal glomerular
function. There was no difference in response in
patients given concurrent corticosteroids. There was
a consistent and significant fall in fasting urinary
creatinine indicating a reduction in net bone loss,
which persisted for the duration of treatment.
Calciuria decreased to normal values in 75% of
patients. Parallel but less marked decreases in
urinary excretion of hydroxyproline were also
observed. Both hypercalcaemia and a rise in
calcium/creatinine ratio occured when treatment
was stopped. Serum activity of alkaline phosphatase
rose progressively throughout treatment and
declined when treatment was stopped. This did not
appear to be due to changes in hepatic function
since no changes in the activity of hepatic
transaminases was noted, and a marked increase in
serum phosphatase activity was observed in 3TREATMENT OF MALIGNANT HYPERCALCAEMIA 667
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Figure 1 Changes in mean serum calcium, serum
alkaline phosphatase, fasting urinary calcium, and
urinary hydroxyproline (SEM) in 17 episodes of
malignant hypercalcaemia during treatment with
clodronate, and in 11 episodes after stopping
treatment. Asterisks denote significance of differences
from values before or immediately after stopping
treatment (*P<0.05; **P<0.01; ***P<0.001).
patients without other biochemical evidence of
hepatic involvement.
No effects were noted on full blood counts. The
only side effect noted was mild gastrointestinal
upset in some patients.
Three patients failed to show a substantial fall in
serum calcium. In two however, a marked fall in
urinary calcium/creatinine was noted (eg Figure 2)
suggesting that the reduction in bone resorption
had been masked by a simultaneous rise in renal
tubular reabsorption for calcium. The remaining
patient failed to show any reduction in serum or
urinary calcium possibly due to inadequate
absorption of the drug.
Discussion
These results indicate that clodronate given by
mouth is an effective hypocalcaemic agent in
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Figure 2 Changes in serum calcium and fasting
urinary calcium in a patient (no 12) who apparently
failed to respond to treatment with clodronate. Note
the fall in urinary calcium during treatment suggesting
that clodronate inhibited bone resorption, but the lack
of effect on serum calcium.
patients with solid tumours. However, the
magnitude of the hypocalcaemic response was less
than in our own series of patients with hyper-
calcaemia due to myeloma treated identically with
clodronate (Paterson et al., 1983). Unfortunately,
assays for the diphosphonates are not widely
available nor easy to interpret (Kanis, 1985), so that
it was not possible to document the bioavailibility
of the drug. Despite this difficulty it is likely that
clodronate decreased bone resorption to a similar
extent in both myeloma and our patients with solid
tumours. Thus net calcium release from bone, as
judged by the calcium/creatinine ratio, was sup-
pressed to a similar extent in myeloma and
carcinoma, which suggests that the less complete
response in patients with carcinoma was due to
other mechanisms. Indeed, in 2 patients in whom
plasma calcium did not change, there was evidence
for effective suppression of excessive bone
resorption. The lack of fall in serum calcium was
probably due to to an increase in renal tubular
reabsorption of calcium, and others (Ralston et al.,
1984) have suggested that increased renal tubular
E
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resorption of calcium is an important component of
malignant hypercalcaemia.
It is unlikely that the hypocalcaemic responses
were due to changes in the state of hydration, as
serum creatinine, albumin and haemocrit did not
change during treatment.
The changes in fasting calcium excretion were
more marked than changes in urinary hydro-
xyproline excretion. This finding is similar to the
experience of others in solid tumours (Chapuy et
al., 1980) and to our findings in myeloma (Paterson
et al., 1983). It is probable that hydroxyprolinuria
is partly due to collagen turnover of tumour tissue
and that this masked the effects of diphosphonate
treatment on bone-derived collagen.
There are now a number of reports that several
different diphosphonates provide a simple and
effective treatment for hypercalcaemia due to
increased bone resorption (Chapuy et al., 1980; van
Breukelen et al., 1979; Jacobs et al., 1981; Douglas
et al., 1980; Mundy et al., 1983; Jung et al., 1981).
The only commercially available diphosphonate
(etidronate) is a powerful inhibitor of bone
resorption but also impairs mineralisation of bone,
particularly when high doses are used (Boyce et al.,
1984). This unwanted effect decreases calcium entry
into bone and may explain the less complete
hypocalcaemic effect of this agent (Kanis et al.,
1983).
The newer diphosphonates (clodronate and
aminopropylidene diphosphonate) which are
currently undergoing clinical evaluation, appear to
have less effect on the mineralisation process. There
have been concerns that clodronate might be
leukaemogenic based on the finding of acute
myeloid leukaemia in 3 patients given clodronate.
Investigation of these patients and surveillance of
patients given clodronate is continuing to assess the
significance of these observations. Our own view is
that this was a coincidental rather than causal
relationship.
Our own studies with clodronate indicate that,
despite its poor absorption from the gastrointestinal
tract (Yakatan et al., 1982), oral administration is
an effective method of controlling bone resorption
which can be inhibited for as long as treatment is
continued. Moreover the long-term administration
of clodronate to patients with breast cancer may
delay the appearance of osteolysis (Elomaa et al.,
1983; Jung et al., 1983). These observations suggest
that the use of diphoshonates may modify the
natural history of skeletal metastases in patients
with solid tumours. Whether or not this might
improve survival is far from clear, but is likely to
decrease considerably the morbidity associated with
hypercalcaemia and7fracture.
RCP is a Wellcome Surgical Fellow and AJPY an MRC
Clinical Research Fellow. We are grateful to the Procter
and Gamble Company, Gentili SpA and Oy Star for
supplies ofclodronate.
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